US Interventional Cardiology Devices Market

The US interventional cardiology devices market is projected to reach USD 17.75 billion by 2031 from USD  12.82 billion in 2026, growing at a CAGR of 6.7% during the forecast period .

The US interventional cardiology devices market is growing owing to the rising prevalence of cardiovascular diseases. Moreover, the rise in the aging population and widespread risk factors, such as obesity, diabetes, hypertension, and lack of exercise, further contribute to the market growth. The clinical preference for minimally invasive, catheter-based procedures over open-heart surgery keeps on accelerating. Hospitals are retaining patients for shorter periods, complications are fewer, and recovery is faster. Moreover, continual technological advancements—drug-eluting and bioresorbable stents, next-generation balloon catheters, intravascular imaging systems (IVUS and OCT), fractional flow reserve (FFR) technologies, and structural heart devices—are substantially enhancing the accuracy, safety, and longevity of the procedure. Not only does the market witness the benefits of favorable reimbursement policies, but also the quick acceptance of new technologies by the hospitals and outpatient surgical centers in the country. Major global manufacturers’ presence in the market, with strong R&D pipelines, also contributed to market growth. Furthermore, the rising volumes of complex coronary and structural heart interventions, enhanced public awareness of early diagnosis and preventive cardiology, and the adoption of AI-powered imaging and navigation tools lead to increased focus on the efficiency of the procedure and the quality of clinical decision-making, driving the market.

To know about the assumptions considered for the study download the pdf brochure

Prominent players operating in the US interventional cardiology devices market are Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), and BIOTRONIK SE & Co. KG (Germany). These players focus on strategies such as product launches to enhance their presence and increase their product portfolio.

For instance, in February 2024, Boston Scientific Corporation invested in catheter and structural heart device manufacturing capabilities in its local plants. The move was designed to cater to the increasing number of coronary interventions, transcatheter valve therapy, and peripheral complex procedure cases, while at the same time, making the supply chain more robust and speeding up the market’s access to next-generation balloon catheters, drug-eluting technologies, and intravascular imaging-enabled devices.

Boston Scientific Corporation (US)

Boston Scientific Corporation is a significant player in the US interventional cardiology devices market. The company’s corpulent and well-integrated portfolio supports coronary, peripheral, and structural heart interventions. It has a tight grip on the drug-eluting stents, balloon catheters, atherectomy systems, and intravascular imaging-compatible devices, which are extensively utilized in US hospitals and ambulatory surgical centers. Hence, it continually invests in R&D, focuses on the treatment of less invasive and complex lesions, and keeps a succession of next-generation technologies, all of which would guarantee its competitive edge. It also has a strong presence in the market due to its strategic acquisitions, technology partnerships, and domestic manufacturing plant expansions. It has a history of being at the forefront of technological advancements and adds the ability to meet the increasing demand as a result of these strategies.

Medtronic (US)

Medtronic is one of the major players in the US interventional cardiology devices market, through its diversified cardiovascular portfolio and strong clinical presence, to keep a competitive position in the coronary and structural heart interventions. The company provides an array of products that include drug-eluting stents, balloon catheters, guidewires, and the latest transcatheter solutions. These are all backed by convincing clinical data and close ties with US healthcare providers. It also concentrates on its R&D and digital technologies, which are giving efficiency and patients a better outcome in heart surgeries. Its massive presence in the US through manufacturing, distribution, and physician training allows for the quick commercialization and acceptance of new devices. On the one hand, the partnerships and the growth of the portfolio have made it easier for the company to cater to the changing clinical needs, which, on the other hand, continue to secure its role as the dominating firm in the US interventional cardiology devices market.

Market Ranking

The US interventional cardiology devices market shows a moderate to high concentration, where a few large multinational companies take up the preponderance of sales revenue. Among the leading companies, Boston Scientific is in the forefront due to the active role it plays in complex coronary interventions and an extensive range of products, which includes drug-eluting stents, balloon catheters, atherectomy systems, intravascular lithotripsy, and a growing structural heart franchise, which gives it the upper hand. Its constant innovation, strong clinical backing, and deep penetration in US cath labs cement its leadership claim. Medtronic is the next market player, to a large extent, taking advantage of its broad cardiovascular portfolio, procedural support technologies, and good relationship with doctors and hospitals that has lasted for years. Abbott, with its comprehensive coronary and structural heart range, continues to be a major market player. Its non-drug-coated stents, intravascular imaging (IVUS and OCT), and physiology-based diagnostic platforms come under this category. Edwards Lifesciences, as the market leader, is most active in the interventional cardiology segment, especially regarding transcatheter valves for therapies. However, its coronary intervention exposure is small.

Related Reports:

US Interventional Cardiology Devices Market by Type (Stents, Balloons, Structural Heart, Angio Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration, Guidewire, Introducer Sheaths), End User (Hospitals, Cardiac Centers) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com